Cytologic hallmarks and differential diagnosis of papillary thyroid carcinoma subtypes

• Published in: Journal of pathology and translational medicine 2024, 58(6), , pp.265-282
• Main Authors: Harahap, Agnes Stephanie, Jung, Chan Kwon
• Format: Article
• Language: English
• Subjects: biopsy, fine-needle; Cancer therapies; Cellular biology; Clinical decision making; diagnostic errors; lymphatic metastasis; Lymphatic system; Medical errors; Medical prognosis; Metastasis; Mutation; prognosis; reference standards; Review; risk assessment; Thyroid cancer; thyroid cancer, papillary; thyroid neoplasms; Tumors; 병리학
• ISSN: 2383-7837; 2383-7845
• DOI: 10.4132/jptm.2024.10.11

Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy, characterized by a range of subtypes that differ in their cytologic features, clinical behavior, and prognosis. Accurate cytologic evaluation of PTC using fine-needle aspiration is essential but can be challenging due to the morphologic diversity among subtypes. This review focuses on the distinct cytologic characteristics of various PTC subtypes, including the classic type, follicular variant, tall cell, columnar cell, hobnail, diffuse sclerosing, Warthin-like, solid/trabecular, and oncocytic PTCs. Each subtype demonstrates unique nuclear features, architectural patterns, and background elements essential for diagnosis and differentiation from other thyroid lesions. Recognizing these distinct cytologic patterns is essential for identifying aggressive subtypes like tall cell, hobnail, and columnar cell PTCs, which have a higher risk of recurrence, metastasis, and poorer clinical outcomes. Additionally, rare subtypes such as diffuse sclerosing and Warthin-like PTCs present unique cytologic profiles that must be carefully interpreted to avoid diagnostic errors. The review also highlights the cytologic indicators of lymph node metastasis and high-grade features, such as differentiated high-grade thyroid carcinoma. The integration of molecular testing can further refine subtype diagnosis by identifying specific genetic mutations. A thorough understanding of these subtype-specific cytologic features and molecular profiles is vital for accurate diagnosis, risk stratification, and personalized management of PTC patients. Future improvements in diagnostic techniques and standardization are needed to enhance cytologic evaluation and clinical decision-making in thyroid cancer.